Zentalis Pharmaceuticals (ZNTL) Price & Analysis

Compare

337 Followers

ZNTL Stock Chart & Stats

$1.49

-$0.17(-5.69%)

At close: Jan 08 4:00 PM EST

$1.49

-$0.17(-5.69%)

Day’s Range― - ―

52-Week Range$1.01 - $4.44

Previous CloseN/A

Volume750.15K

Average Volume (3M)704.34K

Market Cap

$112.53M

Enterprise Value-$178.60M

Total Cash (Recent Filing)$303.43M

Total Debt (Recent Filing)$37.69M

Price to Earnings (P/E)―

Beta1.98

Next Earnings

Mar 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding72,135,450

10 Day Avg. Volume813,604

30 Day Avg. Volume704,342

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.59

Enterprise Value/Revenue-6.65

Enterprise Value/Gross Profit-6.84

Enterprise Value/Ebitda1.00

Forecast

1Y Price Target

$6.71

Price Target Upside350.34% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Efficacy ExpectationsThe prior 31-35% ORR and 4.2-6.3 month mDOR is clearly better than standard of care chemo, and should improve in DENALI Part 2.

Financial StabilityZentalis ended 2Q25 with $303.4M in cash, which the company expects to be sufficient to fund operations into late-2027.

Regulatory ProgressZentalis Pharmaceuticals Inc remains focused on clinical execution and reiterated topline data from Part 2 of the DENALI study of azenosertib, with the potential to support an accelerated approval.

Bears Say

Catalyst TimingThere is a lack of catalysts as azeno's DENALI Part 2a/b top line data in CCNE1+ PROC won't be reported until YE26.

Investor SentimentShares are down -54% YTD vs. XBI's -6% given the lack of catalysts in the near term and low investor confidence in azeno's safety/efficacy profile.

Stock PerformanceAnalyst does not expect the stock to work up from depressed levels in the near term.

Zentalis Pharmaceuticals News

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member...

25d ago

ZNTL

Zentalis Pharmaceuticals Announces New Chief Legal Officer

An update from Zentalis Pharmaceuticals ( ($ZNTL) ) is now available. On August 26, 2025, Zentalis Pharmaceuticals announced...

2M ago

ZNTL

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Zentalis (ZNTL) announced the appointment of James Bucher as chief legal officer and corporate secretary, effective September 18....

2M ago

ZNTL

Zentalis price target lowered to $5 from $6 at Wells Fargo

Wells Fargo lowered the firm’s price target on Zentalis (ZNTL) to $5 from $6 and keeps an Equal...

2M ago

ZNTL

Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals,...

2M ago

ZNTL

Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism

Analyst Derek Archila from Wells Fargo maintained a Hold rating on Zentalis Pharmaceuticals and decreased the price target...

2M ago

ZNTL

Zentalis Pharmaceuticals Reports Improved Financial Results

Zentalis Pharmaceuticals Inc ( ($ZNTL) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ZNTL

Zentalis Pharmaceuticals Reports Q2 2025 Financial Results

The latest update is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Zentalis Pharmaceuticals announced its second quarter 2025...

2M ago

ZNTL

Zentalis management to meet with Oppenheimer

Meetings to be held July 15 and July 17 hosted by Oppenheimer. Published first on TheFly – the...

3M ago

ZNTL

Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On June 17, 2025, Zentalis Pharmaceuticals held its 2025...

4M ago

ZNTL

Zentalis Pharmaceuticals Presents Promising Study Results at ASCO

Zentalis Pharmaceuticals ( ($ZNTL) ) has shared an announcement. Zentalis Pharmaceuticals presented data at the 2025 ASCO Annual...

5M ago

ZNTL

Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals’ Azenosertib

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Zentalis Pharmaceuticals (ZNTL – Research...

5M ago

ZNTL

Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference

The latest announcement is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Zentalis Pharmaceuticals announced its participation in several...

5M ago

ZNTL

Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management

In a report released on May 16, Andrew Berens from Leerink Partners reiterated a Hold rating on Zentalis...

5M ago

ZNTL

ZNTL FAQ

What was Zentalis Pharmaceuticals’s price range in the past 12 months?

Zentalis Pharmaceuticals lowest stock price was $1.01 and its highest was $4.44 in the past 12 months.

What is Zentalis Pharmaceuticals’s market cap?

Zentalis Pharmaceuticals’s market cap is $112.53M.

When is Zentalis Pharmaceuticals’s upcoming earnings report date?

Zentalis Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 136 days.

How were Zentalis Pharmaceuticals’s earnings last quarter?

Zentalis Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $0.224.

Is Zentalis Pharmaceuticals overvalued?

According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zentalis Pharmaceuticals pay dividends?

Zentalis Pharmaceuticals does not currently pay dividends.

What is Zentalis Pharmaceuticals’s EPS estimate?

Zentalis Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 72,135,450 shares outstanding.

What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?

Zentalis Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went up 5.072%.

Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?

Currently, no hedge funds are holding shares in ZNTL

Zentalis Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-49.55%

Trailing 12-Months

Asset Growth

-28.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.

Zentalis Pharmaceuticals (ZNTL) Earnings & Revenues

Historic Earnings Reports

ZNTL Stock 12 Month Forecast

Average Price Target

$6.71

▲(350.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,2.356923076923077,2.993846153846154,3.6307692307692307,4.2676923076923075,4.904615384615385,5.541538461538462,6.178461538461538,6.815384615384615,7.452307692307692,8.08923076923077,8.726153846153846,9.363076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,2.103846153846154,2.4876923076923076,2.871538461538462,3.2553846153846155,3.6392307692307693,4.023076923076923,4.406923076923077,4.7907692307692304,5.174615384615384,5.558461538461538,5.942307692307692,6.326153846153846,{"y":6.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,1.8953846153846154,2.0707692307692307,2.246153846153846,2.4215384615384616,2.596923076923077,2.7723076923076926,2.947692307692308,3.1230769230769235,3.298461538461539,3.4738461538461545,3.6492307692307695,3.8246153846153845,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.31,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >